Literature DB >> 32068025

Toward Genetic Prediction of Nonalcoholic Fatty Liver Disease Trajectories: PNPLA3 and Beyond.

Marcin Krawczyk1, Roman Liebe2, Frank Lammert3.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is on the verge of becoming the leading cause of liver disease. NAFLD develops at the interface between environmental factors and inherited predisposition. Genome-wide association studies, followed by exome-wide analyses, led to identification of genetic risk variants (eg, PNPLA3, TM6SF2, and SERPINA1) and key pathways involved in fatty liver disease pathobiology. Functional studies improved our understanding of these genetic factors and the molecular mechanisms underlying the trajectories from fat accumulation to fibrosis, cirrhosis, and cancer over time. Here, we summarize key NAFLD risk genes and illustrate their interactions in a 3-dimensional "risk space." Although NAFLD genomics sometimes appears to be "lost in translation," we envision clinical utility in trial design, outcome prediction, and NAFLD surveillance.
Copyright © 2020 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adiponutrin; Genetic Risk Score; Genomics; Nonalcoholic Steatohepatitis; Risk Factor; Risk Prediction

Mesh:

Substances:

Year:  2020        PMID: 32068025     DOI: 10.1053/j.gastro.2020.01.053

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  19 in total

1.  Analyses of DNA Methylation Involved in the Activation of Nuclear Karyopherin Alpha 2 Leading to Identify the Progression and Prognostic Significance Across Human Breast Cancer.

Authors:  Xiangrong Cui; Xuan Jing; Xueqing Wu; Jing Xu; Zhuang Liu; Kai Huo; Hongwei Wang
Journal:  Cancer Manag Res       Date:  2020-08-03       Impact factor: 3.989

Review 2.  From the origin of NASH to the future of metabolic fatty liver disease.

Authors:  Andreas Geier; Dina Tiniakos; Helmut Denk; Michael Trauner
Journal:  Gut       Date:  2021-02-25       Impact factor: 23.059

Review 3.  Emerging Role of Genomic Analysis in Clinical Evaluation of Lean Individuals With NAFLD.

Authors:  Sílvia Vilarinho; Veeral Ajmera; Melanie Zheng; Rohit Loomba
Journal:  Hepatology       Date:  2021-10       Impact factor: 17.298

4.  Liver-Specific Deletion of Mouse Tm6sf2 Promotes Steatosis, Fibrosis, and Hepatocellular Cancer.

Authors:  Elizabeth P Newberry; Zoe Hall; Yan Xie; Elizabeth A Molitor; Peter O Bayguinov; Gregory W Strout; James A J Fitzpatrick; Elizabeth M Brunt; Julian L Griffin; Nicholas O Davidson
Journal:  Hepatology       Date:  2021-05-22       Impact factor: 17.298

Review 5.  Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease.

Authors:  Dae Ho Lee
Journal:  Endocrinol Metab (Seoul)       Date:  2020-06-24

6.  The association between SNPs rs1800591 and rs3816873 of the MTTP gene and nonalcoholic fatty liver disease: A meta-analysis.

Authors:  Jie Tan; Jian Zhang; Zhenzhen Zhao; Jie Zhang; Mengzhen Dong; Xuefeng Ma; Shousheng Liu; Yongning Xin
Journal:  Saudi J Gastroenterol       Date:  2020-07-23       Impact factor: 2.485

Review 7.  Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?

Authors:  Agostino Di Ciaula; Salvatore Passarella; Harshitha Shanmugam; Marica Noviello; Leonilde Bonfrate; David Q-H Wang; Piero Portincasa
Journal:  Int J Mol Sci       Date:  2021-05-20       Impact factor: 5.923

8.  PNPLA3 and SERPINA1 Variants Are Associated with Severity of Fatty Liver Disease at First Referral to a Tertiary Center.

Authors:  Georg Semmler; Lorenz Balcar; Hannes Oberkofler; Stephan Zandanell; Michael Strasser; David Niederseer; Alexandra Feldman; Felix Stickel; Pavel Strnad; Christian Datz; Bernhard Paulweber; Elmar Aigner
Journal:  J Pers Med       Date:  2021-03-01

Review 9.  Precision medicine for pancreatic diseases.

Authors:  Celeste A Shelton; David C Whitcomb
Journal:  Curr Opin Gastroenterol       Date:  2020-09       Impact factor: 2.741

Review 10.  Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease.

Authors:  Anne Fougerat; Alexandra Montagner; Nicolas Loiseau; Hervé Guillou; Walter Wahli
Journal:  Cells       Date:  2020-07-08       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.